ID Connect’s clinical consultant Erin McCreary, PharmD, BCPS, BCIDP, commented on the demise of Evusheld in Time Magazine’s Feb. 8, 2023, online edition. The article, titled “Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19,” explores the effects of the end of the pandemic emergency declarations in May 2023 and the FDA’s revoked emergency-use authorization of Evusheld, a therapy first authorized in Dec. 2021.
You might also like…
How Telemedicine is Reshaping Infectious Diseases Care in Community Hospitals
Infectious Disease Connect Physicians Recognized with UPMC Physician Excellence Awards
Infectious Disease Connect’s ILÚM Insight Receives CDC Certification as a Validated Antimicrobial Use Reporting Solution